{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T09:48:12Z","timestamp":1767260892130,"version":"3.37.3"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T00:00:00Z","timestamp":1626912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T00:00:00Z","timestamp":1626912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s40272-021-00461-3","type":"journal-article","created":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T15:03:06Z","timestamp":1626966186000},"page":"445-455","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Secondary Dysgammaglobulinemia in Children with Hematological Malignancies Treated with Targeted Therapies"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4294-2605","authenticated-orcid":false,"given":"Athanasios","family":"Tragiannidis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas H.","family":"Groll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,22]]},"reference":[{"key":"461_CR1","doi-asserted-by":"publisher","first-page":"626","DOI":"10.3389\/fimmu.2014.00626","volume":"5","author":"N Compagno","year":"2014","unstructured":"Compagno N, Malipiero G, Cinetto F, Agostini C. Immunoglobulin replacement therapy in secondary hypogammaglobulinemia. Front Immunol. 2014;5:626.","journal-title":"Front Immunol"},{"key":"461_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3389\/fimmu.2019.00033","volume":"10","author":"SY Patel","year":"2019","unstructured":"Patel SY, Carbone J, Jolles S. The expanding field of secondary antibody deficiency: causes, diagnosis, and management. Front Immunol. 2019;10:33.","journal-title":"Front Immunol"},{"key":"461_CR3","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.pcl.2019.06.010","volume":"66","author":"M El-Bohy","year":"2019","unstructured":"El-Bohy M, Poowuttikul P, Secord E. Humoral immune deficiencies of childhood. Pediatr Clin N Am. 2019;66:897\u2013903.","journal-title":"Pediatr Clin N Am"},{"issue":"Suppl 3","key":"461_CR4","doi-asserted-by":"publisher","first-page":"3056","DOI":"10.1111\/trf.15020","volume":"58","author":"Y Gernez","year":"2018","unstructured":"Gernez Y, Baker MG, Maglione PJ. Humoral immunodeficiencies: conferred risk of infections and benefits of immunoglobulin replacement therapy. Transfusion. 2018;58(Suppl 3):3056\u201364.","journal-title":"Transfusion"},{"key":"461_CR5","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.humimm.2018.10.015","volume":"8","author":"T Smith","year":"2019","unstructured":"Smith T, Cunningham-Rundles C. Primary B-cell immunodeficiencies. Hum Immunol. 2019;8:351\u201362.","journal-title":"Hum Immunol"},{"key":"461_CR6","doi-asserted-by":"publisher","first-page":"571","DOI":"10.7861\/clinmedicine.16-6-571","volume":"16","author":"S Srivastava","year":"2016","unstructured":"Srivastava S, Wood P. Secondary antibody deficiency\u2014causes and approach to diagnosis. Clin Med. 2016;16:571\u20136.","journal-title":"Clin Med"},{"key":"461_CR7","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/cei.12915","volume":"188","author":"S Jolles","year":"2017","unstructured":"Jolles S, Chapel H, Litzman J. When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach. Clin Exp Immunol. 2017;188:333\u201341.","journal-title":"Clin Exp Immunol"},{"key":"461_CR8","doi-asserted-by":"publisher","first-page":"625707","DOI":"10.3389\/fonc.2021.625707","volume":"11","author":"D Ragoonanan","year":"2021","unstructured":"Ragoonanan D, Khazal SJ, Mejia R, Ewing L, Durand JB, Bashoura L, et al. Case discussion and literature review: cancer immunotherapy, severe immune-related adverse events, multi-inflammatory syndrome, and severe acute respiratory syndrome coronavirus. Front Oncol. 2021;11:625707.","journal-title":"Front Oncol"},{"key":"461_CR9","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2020-7-2","author":"D Conde-Royo","year":"2020","unstructured":"Conde-Royo D, Ju\u00e1rez-Salcedo LM, Dalia S. Management of adverse effects of new monoclonal antibody treatments in acute lymphoblastic leukemia. Drugs Context. 2020. https:\/\/doi.org\/10.7573\/dic.2020-7-2.","journal-title":"Drugs Context"},{"key":"461_CR10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1053\/j.seminhematol.2020.11.001","volume":"57","author":"E Curran","year":"2020","unstructured":"Curran E, O\u2019Brien M. Role of blinatumomab, inotuzumab, and CAR T-cells: which to choose and how to sequence for patients with relapsed disease. Semin Hematol. 2020;57:157\u201363.","journal-title":"Semin Hematol"},{"key":"461_CR11","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s11684-020-0759-8","volume":"14","author":"CH Pui","year":"2020","unstructured":"Pui CH. Precision medicine in acute lymphoblastic leukemia. Front Med. 2020;14:689\u2013700.","journal-title":"Front Med"},{"key":"461_CR12","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40272-020-00413-3","volume":"22","author":"S Jasinski","year":"2020","unstructured":"Jasinski S, Deoseyes FA, Yametti GC, Pierro J, Raetz E, et al. Immunotherapy in pediatric B-cell acute lymphoblastic leukemia: advances and ongoing challenges. Paediatr Drugs. 2020;22:485\u201399.","journal-title":"Paediatr Drugs"},{"key":"461_CR13","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/ofid\/ofaa121","volume":"7","author":"SB Vora","year":"2020","unstructured":"Vora SB, Waghmare A, Englund JA, Qu P, Gardner RA, Hill JA. Infectious complications following CD19 chimeric antigen receptor T-cell therapy for children, adolescents, and young adults. Open Forum Infect Dis. 2020;7:121.","journal-title":"Open Forum Infect Dis"},{"key":"461_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00474-4","author":"D Ragoonanan","year":"2021","unstructured":"Ragoonanan D, Khazal SJ, Abdel-Azim H, McCall D, Cuglievan B, Tambaro FP, et al. Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. Nat Rev Clin Oncol. 2021. https:\/\/doi.org\/10.1038\/s41571-021-00474-4 (Epub ahead of print).","journal-title":"Nat Rev Clin Oncol"},{"key":"461_CR15","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s15010-020-01521-5","volume":"49","author":"I Los-Arcos","year":"2021","unstructured":"Los-Arcos I, Iacoboni G, Aguilar-Guisado M, Alsina-Manrique L, D\u00edaz de Heredia C, Fortuny-Guasch C, et al. Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper. Infection. 2021;49:215\u201331.","journal-title":"Infection"},{"key":"461_CR16","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3390\/jof7030186","volume":"7","author":"I Kyriakidis","year":"2021","unstructured":"Kyriakidis I, Vasileiou E, Rossig C, Roilides E, Groll AH, Tragiannidis A. Invasive fungal diseases in children with hematological malignancies treated with therapies that target cell surface antigens: monoclonal antibodies, immune checkpoint inhibitors and CAR T-cell therapies. J Fungi (Basel). 2021;7:186.","journal-title":"J Fungi (Basel)."},{"unstructured":"European Medicines Agency (EMEA). Blincyto. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/blincyto-epar-product-information_en.pdf. Accessed on 8 Apr 2021.","key":"461_CR17"},{"unstructured":"US Food & Drug Administration (FDA). Blincyto, summary of product characteristics. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125557s013lbl.pdf. Accessed on 19 Jun 2021.","key":"461_CR18"},{"unstructured":"European Medicines Agency (EMEA). Besponsa. Summary of product characteristics. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761040s000lbl.pdf. Accessed on 8 Apr 2021.","key":"461_CR19"},{"unstructured":"US Food & Drug Administration (FDA). Besponsa. Summary of product characteristics. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125557s013lbl.pdf. Accessed on 19 Jun 2021.","key":"461_CR20"},{"unstructured":"European Medicines Agency (EMEA). MabThera. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mabthera-epar-product-information_en.pdf. Accessed on 8 Apr 2021","key":"461_CR21"},{"unstructured":"US Food & Drug Administration (FDA). Mabthera. Summary of product characteristics. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/103705s5367s5388lbl.pdf. Accessed on 19 Jun 2021.","key":"461_CR22"},{"unstructured":"European Medicines Agency (EMEA). Darzalex. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/darzalex-epar-product-information_el.pdf. Accessed on 8 Apr 2021.","key":"461_CR23"},{"unstructured":"US Food & Drug Administration (FDA). Darzalex summary of product characteristics. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761036s013lbl.pdf. Accessed on 19 Jun 2021.","key":"461_CR24"},{"key":"461_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2020.101225","volume":"33","author":"N Jammal","year":"2020","unstructured":"Jammal N, Chew S, Jabbour E, Kantarjian H. Antibody based therapy in relapsed acute lymphoblastic leukemia. Best Pract Res Clin Haematol. 2020;33: 101225. https:\/\/doi.org\/10.1016\/j.beha.2020.101225.","journal-title":"Best Pract Res Clin Haematol"},{"key":"461_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2020.101226","volume":"33","author":"S Chew","year":"2020","unstructured":"Chew S, Jammal N, Kantarjian H, Jabbour E. Monoclonal antibodies in frontline acute lymphoblastic leukemia. Best Pract Res Clin Haematol. 2020;33: 101226. https:\/\/doi.org\/10.1016\/j.beha.2020.101226.","journal-title":"Best Pract Res Clin Haematol"},{"key":"461_CR27","doi-asserted-by":"publisher","first-page":"478","DOI":"10.23736\/S0026-4806.20.07031-7","volume":"111","author":"F Lanza","year":"2020","unstructured":"Lanza F, Maffini E, Saraceni F, Massari E, Rondoni M, Daghia G, Olivieri A, Cerchione C, Martinelli G. New monoclonal antibodies and tyrosine kinase inhibitors in B-cell acute lymphoblastic leukemia. Minerva Med. 2020;111:478\u201390. https:\/\/doi.org\/10.23736\/S0026-4806.20.07031-7.","journal-title":"Minerva Med"},{"key":"461_CR28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13045-019-0703-z","volume":"12","author":"D Liu","year":"2019","unstructured":"Liu D, Zhao J, Song Y, Luo X, Yang T. Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia. J Hematol Oncol. 2019;12:15. https:\/\/doi.org\/10.1186\/s13045-019-0703-z.","journal-title":"J Hematol Oncol"},{"key":"461_CR29","doi-asserted-by":"publisher","first-page":"204062071989989","DOI":"10.1177\/2040620719899897","volume":"11","author":"T Jain","year":"2020","unstructured":"Jain T, Litzow MR. Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia. Ther Adv Hematol. 2020;11:2040620719899897. https:\/\/doi.org\/10.1177\/2040620719899897.","journal-title":"Ther Adv Hematol"},{"key":"461_CR30","doi-asserted-by":"publisher","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","volume":"121","author":"DT Teachey","year":"2013","unstructured":"Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013;121:5154\u20137. https:\/\/doi.org\/10.1182\/blood-2013-02-485623.","journal-title":"Blood"},{"key":"461_CR31","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00277-018-3497-0","volume":"98","author":"AS Stein","year":"2019","unstructured":"Stein AS, Schiller G, Benjamin R, Jia C, Zhang A, Zhu M, Zimmerman Z, et al. Neurologic adverse events in patients with relapsed\/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors. Ann Hematol. 2019;98:159\u201367. https:\/\/doi.org\/10.1007\/s00277-018-3497-0.","journal-title":"Ann Hematol"},{"key":"461_CR32","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/bcj.2014.64.PMID:25192414;PMCID:PMC4183773","volume":"4","author":"G Zugmaier","year":"2014","unstructured":"Zugmaier G, Topp MS, Alekar S, Viardot A, Horst HA, Neumann S, et al. Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia. Blood Cancer J. 2014;4:244. https:\/\/doi.org\/10.1038\/bcj.2014.64.PMID:25192414;PMCID:PMC4183773.","journal-title":"Blood Cancer J"},{"key":"461_CR33","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N, Fielding AK, Schuh AC, Ribera JM, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376:836\u201347. https:\/\/doi.org\/10.1056\/NEJMoa1609783.","journal-title":"N Engl J Med"},{"key":"461_CR34","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","volume":"29","author":"MS Topp","year":"2011","unstructured":"Topp MS, Kufer P, G\u00f6kbuget N, Goebeler M, Klinger M, Neumann S, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29:2493\u20138. https:\/\/doi.org\/10.1200\/JCO.2010.32.7270.","journal-title":"J Clin Oncol"},{"key":"461_CR35","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/ejh.13569","volume":"106","author":"M Queudeville","year":"2021","unstructured":"Queudeville M, Schlegel P, Heinz AT, Lenz T, D\u00f6ring M, Holzer U, et al. Blinatumomab in pediatric patients with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia. Eur J Haematol. 2021;106:473\u201383. https:\/\/doi.org\/10.1111\/ejh.13569.","journal-title":"Eur J Haematol"},{"key":"461_CR36","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1111\/bjh.17382","volume":"193","author":"E Mikhailova","year":"2021","unstructured":"Mikhailova E, Semchenkova A, Illarionova O, Kashpor S, Brilliantova V, Zakharova E, et al. Relative expansion of CD19-negative very-early normal B-cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR-T cell therapy: implications for flow cytometric detection of minimal residual disease. Br J Haematol. 2021;193:602\u201312. https:\/\/doi.org\/10.1111\/bjh.17382.","journal-title":"Br J Haematol"},{"key":"461_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28922","volume":"68","author":"R Sutton","year":"2021","unstructured":"Sutton R, Pozza LD, Khaw SL, Fraser C, Revesz T, Chamberlain J, et al. Outcomes for Australian children with relapsed\/refractory acute lymphoblastic leukaemia treated with blinatumomab. Pediatr Blood Cancer. 2021;68: e28922. https:\/\/doi.org\/10.1002\/pbc.28922.","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"461_CR38","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41408-020-00342-x.Erratum.In:BloodCancerJ.2021;11:28","volume":"10","author":"F Locatelli","year":"2020","unstructured":"Locatelli F, Zugmaier G, Mergen N, Bader P, Jeha S, Schlegel PG, et al. Blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study. Blood Cancer J. 2020;10(7):77. https:\/\/doi.org\/10.1038\/s41408-020-00342-x.Erratum.In:BloodCancerJ.2021;11:28.","journal-title":"Blood Cancer J"},{"issue":"9","key":"461_CR39","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1001\/jama.2021.0669","volume":"325","author":"PA Brown","year":"2021","unstructured":"Brown PA, Ji L, Xu X, Devidas M, Hogan LE, Borowitz MJ, et al. Effect of Postreinduction Therapy Consolidation With blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of b-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325(9):833\u201342. https:\/\/doi.org\/10.1001\/jama.2021.0669.","journal-title":"JAMA"},{"key":"461_CR40","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2021.0987","volume":"325","author":"F Locatelli","year":"2021","unstructured":"Locatelli F, Zugmaier G, Rizzari C, Morris JD, Gruhn B, Klingebiel T, et al. Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse b-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325:843\u201354. https:\/\/doi.org\/10.1001\/jama.2021.0987.","journal-title":"JAMA"},{"key":"461_CR41","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40272-020-00413-3","volume":"22","author":"S Jasinski","year":"2020","unstructured":"Jasinski S, De Los Reyes FA, Yametti GC, Pierro J, Raetz E, Carroll WL. Immunotherapy in pediatric b-cell acute lymphoblastic leukemia: advances and ongoing challenges. Paediatr Drugs. 2020;22:485\u201399. https:\/\/doi.org\/10.1007\/s40272-020-00413-3.","journal-title":"Paediatr Drugs"},{"issue":"Suppl 2","key":"461_CR42","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.1016\/j.cmi.2018.03.022","volume":"24","author":"L Drgona","year":"2018","unstructured":"Drgona L, Gudiol C, Lanini S, Salzberger B, Ippolito G, Mikulska M. ESCMID study group for infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). Clin Microbiol Infect. 2018;24(Suppl 2):S83\u201394. https:\/\/doi.org\/10.1016\/j.cmi.2018.03.022.","journal-title":"Clin Microbiol Infect"},{"key":"461_CR43","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1200\/JCO.2012.42.7211","volume":"31","author":"L Fayad","year":"2013","unstructured":"Fayad L, Offner F, Smith MR, Verhoef G, Johnson P, Kaufman JL, et al. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I\/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol. 2013;31:573\u201383. https:\/\/doi.org\/10.1200\/JCO.2012.42.7211.","journal-title":"J Clin Oncol"},{"key":"461_CR44","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375:740\u201353. https:\/\/doi.org\/10.1056\/NEJMoa1509277.","journal-title":"N Engl J Med"},{"key":"461_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107565","volume":"95","author":"Z Zian","year":"2021","unstructured":"Zian Z, Berry SPD, Bahmaie N, Ghotbi D, Kashif A, Madkaikar M, et al. The clinical efficacy of Rituximab administration in autoimmunity disorders, primary immunodeficiency diseases and malignancies. Int Immunopharmacol. 2021;95: 107565. https:\/\/doi.org\/10.1016\/j.intimp.2021.107565.","journal-title":"Int Immunopharmacol"},{"key":"461_CR46","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2165\/00003495-200363080-00005","volume":"63","author":"GL Plosker","year":"2003","unstructured":"Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin\u2019s lymphoma and chronic lymphocytic leukaemia. Drugs. 2003;63:803\u201343. https:\/\/doi.org\/10.2165\/00003495-200363080-00005.","journal-title":"Drugs"},{"key":"461_CR47","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/jI.2008.05.011","volume":"20","author":"RP Taylor","year":"2008","unstructured":"Taylor RP, Lindorfer MA. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr Opin Immunol. 2008;20:444\u20139. https:\/\/doi.org\/10.1016\/jI.2008.05.011.","journal-title":"Curr Opin Immunol"},{"key":"461_CR48","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/1756-8722-5-64","volume":"5","author":"S Cang","year":"2012","unstructured":"Cang S, Mukhi N, Wang K, Liu D. Novel CD20 monoclonal antibodies for lymphoma therapy. J Hematol Oncol. 2012;5:64. https:\/\/doi.org\/10.1186\/1756-8722-5-64.","journal-title":"J Hematol Oncol"},{"key":"461_CR49","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14633","volume":"34","author":"H Mahmoudi","year":"2021","unstructured":"Mahmoudi H, Tavakolpour S, Balighi K, Farid AS, Nili A, Jan D, Daneshpazhooh M. Rituximab in practice: clinical evaluation of patients with pemphigus after rituximab administration. Dermatol Ther. 2021;34: e14633. https:\/\/doi.org\/10.1111\/dth.14633.","journal-title":"Dermatol Ther"},{"key":"461_CR50","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.5849","volume":"11","author":"M Samson","year":"2019","unstructured":"Samson M, Fraser W, Lebowitz D. Treatments for primary immune thrombocytopenia: a review. Cureus. 2019;11: e5849. https:\/\/doi.org\/10.7759\/cureus.5849.","journal-title":"Cureus."},{"key":"461_CR51","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1080\/17474086.2019.1636644","volume":"12","author":"X Dou","year":"2019","unstructured":"Dou X, Yang R. Current and emerging treatments for immune thrombocytopenia. Expert Rev Hematol. 2019;12:723\u201332. https:\/\/doi.org\/10.1080\/17474086.2019.1636644.","journal-title":"Expert Rev Hematol"},{"key":"461_CR52","doi-asserted-by":"publisher","first-page":"4034","DOI":"10.3390\/jcm9124034","volume":"9","author":"I Murakhovskaya","year":"2020","unstructured":"Murakhovskaya I. Rituximab use in warm and cold autoimmune hemolytic anemia. J Clin Med. 2020;9:4034. https:\/\/doi.org\/10.3390\/jcm9124034.","journal-title":"J Clin Med"},{"key":"461_CR53","first-page":"189","volume":"87","author":"F Zaja","year":"2002","unstructured":"Zaja F, Iacona I, Masolini P, Russo D, Sperotto A, Prosdocimo S, et al. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica. 2002;87:189\u201395.","journal-title":"Haematologica"},{"key":"461_CR54","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","volume":"13","author":"C Casulo","year":"2013","unstructured":"Casulo C, Maragulia J, Zelenetz AD. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk. 2013;13:106\u201311. https:\/\/doi.org\/10.1016\/j.clml.2012.11.011.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"461_CR55","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/bmt.2008.385","volume":"43","author":"K Masjosthusmann","year":"2009","unstructured":"Masjosthusmann K, Ehlert K, Eing BR, Roth J, Koehler G, Juergens H, Fruehwald M, Groll AH. Delay in B-lymphocyte recovery and function following rituximab for EBV-associated lymphoproliferative disease early post-allogeneic hematopoietic SCT. Bone Marrow Transplant. 2009;43:679\u201384. https:\/\/doi.org\/10.1038\/bmt.2008.385.","journal-title":"Bone Marrow Transplant"},{"key":"461_CR56","doi-asserted-by":"publisher","DOI":"10.1111\/petr.13519","volume":"23","author":"FK Chiou","year":"2019","unstructured":"Chiou FK, Beath SV, Patel M, Gupte GL. Hypogammaglobulinemia and bacterial infections following pediatric post-transplant lymphoproliferative disorder in the rituximab era. Pediatr Transplant. 2019;23: e13519. https:\/\/doi.org\/10.1111\/petr.13519.","journal-title":"Pediatr Transplant"},{"key":"461_CR57","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/bjh.15944","volume":"186","author":"A Maschan","year":"2019","unstructured":"Maschan A, Myakova N, Aleinikova O, Abugova Y, Ponomareva N, Belogurova M, et al. Rituximab and reduced-intensity chemotherapy in children and adolescents with mature B-cell lymphoma: interim results for 231 patients enrolled in the second Russian-Belorussian multicentre study B-NHL-2010M. Br J Haematol. 2019;186:477\u201383. https:\/\/doi.org\/10.1111\/bjh.15944.","journal-title":"Br J Haematol"},{"key":"461_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/cancers7010305","author":"J Worch","year":"2015","unstructured":"Worch J, Makarova O, Burkhardt B. Immunreconstitution and infectious complications after rituximab treatment in children and adolescents: what do we know and what can we learn from adults? Cancers (Basel). 2015. https:\/\/doi.org\/10.3390\/cancers7010305.","journal-title":"Cancers (Basel)"},{"unstructured":"Meinhardt A, Schadwill S, Zimmermann M, Gruhn B, Behnisch W, Becker M, et al. Serum immunoglobulin levels in children and adolescents after B-NHL BFM chemotherapy with and without one dose of rituximab. 2009;3:Abstract 036","key":"461_CR59"},{"key":"461_CR60","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1097\/MPH.0b013e31829d4900","volume":"36","author":"EV Samochatova","year":"2014","unstructured":"Samochatova EV, Maschan AA, Shelikhova LN, Myakova NV, Belogurova MB, et al. Therapy of advanced-stage mature B-cell lymphoma and leukemia in children and adolescents with rituximab and reduced intensity induction chemotherapy (B-NHL 2004M protocol): the results of a multicenter study. J Pediatr Hematol Oncol. 2014;36:395\u2013401. https:\/\/doi.org\/10.1097\/MPH.0b013e31829d4900.","journal-title":"J Pediatr Hematol Oncol"},{"key":"461_CR61","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28682","volume":"67","author":"S Srinivasan","year":"2020","unstructured":"Srinivasan S, Roy Moulik N, Kc A, Narula G, Sankaran H, Prasad M, Dhamne C, Cheriyalinkal Parambil B, Shah S, Shet T, Sridhar E, Gujral S, Banavali S. Increased toxicities in children with Burkitt lymphoma treated with rituximab: Experience from a tertiary cancer center in India. Pediatr Blood Cancer. 2020;67: e28682. https:\/\/doi.org\/10.1002\/pbc.28682.","journal-title":"Pediatr Blood Cancer"},{"key":"461_CR62","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa1915315","volume":"382","author":"V Minard-Colin","year":"2020","unstructured":"Minard-Colin V, Aup\u00e9rin A, Pillon M, Burke GAA, Barkauskas DA, Wheatley K, et al. European intergroup for childhood non-hodgkin lymphoma children\u2019s oncology group rituximab for high-risk mature B-cell non-hodgkin\u2019s lymphoma in children. N Engl J Med. 2020;382:2207\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1915315.","journal-title":"N Engl J Med"},{"unstructured":"European Medicines Agency (EMEA). Kymriah. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kymriah-epar-product-information_en.pdf. Accessed on 8 Apr 2021.","key":"461_CR63"},{"unstructured":"European Medicines Agency (EMEA). Tecartus. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tecartus-epar-product-information_en.pdf. Accessed on 8 Apr 2021","key":"461_CR64"},{"unstructured":"US Food & Drug Administration (FDA). Kymriah. Summary of product characteristics. https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/kymriah-tisagenlecleucel. Accessed on 19 Jun 2021.","key":"461_CR65"},{"key":"461_CR66","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, Milone MC, Levine BL, June CH. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368:1509\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1215134.","journal-title":"N Engl J Med"},{"issue":"16","key":"461_CR67","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1407222.","journal-title":"N Engl J Med"},{"key":"461_CR68","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1709866.","journal-title":"N Engl J Med"},{"key":"461_CR69","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018;24:731\u20138. https:\/\/doi.org\/10.1038\/s41591-018-0041-7.","journal-title":"Nat Med"},{"key":"461_CR70","doi-asserted-by":"publisher","first-page":"ofaa121","DOI":"10.1093\/ofid\/ofaa121","volume":"7","author":"SB Vora","year":"2020","unstructured":"Vora SB, Waghmare A, Englund JA, Qu P, Gardner RA, Hill JA. Infectious complications following CD19 chimeric antigen receptor T-cell therapy for children, adolescents, and young adults. Open Forum Infect Dis. 2020;7:ofaa121. https:\/\/doi.org\/10.1093\/ofid\/ofaa121.","journal-title":"Open Forum Infect Dis"},{"key":"461_CR71","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/s41409-020-01027-6","volume":"56","author":"A Dey\u00e0-Mart\u00ednez","year":"2021","unstructured":"Dey\u00e0-Mart\u00ednez A, Alonso-Saladrigues A, Garc\u00eda AP, Faura A, Torrebadell M, Vlagea A, et al. Kinetics of humoral deficiency in CART19-treated children and young adults with acute lymphoblastic leukaemia. Bone Marrow Transplant. 2021;56:376\u201386. https:\/\/doi.org\/10.1038\/s41409-020-01027-6.","journal-title":"Bone Marrow Transplant"},{"key":"461_CR72","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","volume":"26","author":"A Cordeiro","year":"2020","unstructured":"Cordeiro A, Bezerra ED, Hirayama AV, Hill JA, Wu QV, Voutsinas J, et al. Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells. Biol Blood Marrow Transplant. 2020;26:26\u201333. https:\/\/doi.org\/10.1016\/j.bbmt.2019.08.003.","journal-title":"Biol Blood Marrow Transplant"},{"key":"461_CR73","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1111\/bjh.15789","volume":"185","author":"ML Metzger","year":"2019","unstructured":"Metzger ML, Mauz-K\u00f6rholz C. Epidemiology, outcome, targeted agents and immunotherapy in adolescent and young adult non-Hodgkin and Hodgkin lymphoma. Br J Haematol. 2019;185:1142\u201357. https:\/\/doi.org\/10.1111\/bjh.15789.","journal-title":"Br J Haematol"},{"key":"461_CR74","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1586\/17474086.2015.1081562.P","volume":"8","author":"K Dumaswala","year":"2015","unstructured":"Dumaswala K, Mehta A. Novel agents for the treatment of Hodgkin lymphoma. Expert Rev Hematol. 2015;8:659\u201367. https:\/\/doi.org\/10.1586\/17474086.2015.1081562.P.","journal-title":"Expert Rev Hematol"},{"issue":"11","key":"461_CR75","doi-asserted-by":"publisher","first-page":"389","DOI":"10.2147\/JBM.S250581","volume":"27","author":"L Castagna","year":"2020","unstructured":"Castagna L, Santoro A, Carlo-Stella C. Salvage therapy for Hodgkin\u2019s lymphoma: a review of current regimens and outcomes. J Blood Med. 2020;27(11):389\u2013403. https:\/\/doi.org\/10.2147\/JBM.S250581.","journal-title":"J Blood Med."},{"unstructured":"European Medicines Agency (EMEA). Keytruda. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/keytruda-epar-product-information_en.pdf. Accessed on 8 Apr 2021.","key":"461_CR76"},{"unstructured":"US Food & Drug Administration (FDA). Keytruda, Summary of product characteristics. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125514s096lbl.pdf. Accessed on 19 Jun 2021.","key":"461_CR77"},{"key":"461_CR78","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1470-2045(19)30671-0","volume":"21","author":"B Geoerger","year":"2020","unstructured":"Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, et al. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1\u20132 trial. Lancet Oncol. 2020;21:121\u201333. https:\/\/doi.org\/10.1016\/S1470-2045(19)30671-0.","journal-title":"Lancet Oncol"},{"unstructured":"European Medicines Agency (EMEA). Opdivo. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/opdivo-epar-product-information_en.pdf. Accessed on 8 Apr 2021.","key":"461_CR79"},{"key":"461_CR80","doi-asserted-by":"publisher","first-page":"7095","DOI":"10.21873\/anticanres.14738","volume":"40","author":"A Marja\u0143ska","year":"2020","unstructured":"Marja\u0143ska A, Drogosiewicz M, Dembowska-Bagi\u0143ska B, Pawi\u0143ska-W\u0105sikowska K, Balwierz W, Bobeff K, et al. Nivolumab for the treatment of advanced pediatric malignancies. Anticancer Res. 2020;40:7095\u2013100. https:\/\/doi.org\/10.21873\/anticanres.14738.","journal-title":"Anticancer Res"},{"key":"461_CR81","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S1470-2045(20)30023-1","volume":"21","author":"KL Davis","year":"2020","unstructured":"Davis KL, Fox E, Merchant MS, Reid JM, Kudgus RA, Liu X, et al. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1\u20132 trial. Lancet Oncol. 2020;21:541\u201350.","journal-title":"Lancet Oncol"},{"unstructured":"European Medicines Agency (EMEA). Glivec. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/glivec. Accessed on 8 Apr 2021.","key":"461_CR82"},{"unstructured":"US Food & Drug Administration (FDA). Glivec, Summary of product characteristics. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/021588s024lbl.pdf. Accessed on 19 Jun 2021.","key":"461_CR83"},{"unstructured":"European Medicines Agency (EMEA). Sprycel. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/sprycel-epar-product-information_en.pdf. Accessed on 8 Apr 2021.","key":"461_CR84"},{"unstructured":"US Food & Drug Administration (FDA). Sprycel, summary of product characteristics. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021986s020lbl.pdf. Accessed on 19 Jun 2021.","key":"461_CR85"},{"unstructured":"European Medicines Agency (EMEA). Tasigna. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tasigna-epar-product-information_en.pdf. Accessed on 8 Apr 2021.","key":"461_CR86"},{"unstructured":"US Food & Drug Administration (FDA). Tasigna, Summary of product characteristics. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022068s004s005lbl.pdf. Accessed on 19 Jun 2021.","key":"461_CR87"},{"key":"461_CR88","doi-asserted-by":"publisher","first-page":"e27422","DOI":"10.1002\/pbc.27422","volume":"65","author":"D Drozdov","year":"2018","unstructured":"Drozdov D, Bonaventure A, Nakata K, Suttorp M, Belot A. Temporal trends in the proportion of \u201ccure\u201d in children, adolescents, and young adults diagnosed with chronic myeloid leukemia in England: a population-based study. Pediatr Blood Cancer. 2018;65:e27422. https:\/\/doi.org\/10.1002\/pbc.27422.","journal-title":"Pediatr Blood Cancer"},{"key":"461_CR89","doi-asserted-by":"publisher","first-page":"e042814","DOI":"10.1136\/bmjopen-2020-042814","volume":"11","author":"M Chen","year":"2021","unstructured":"Chen M, Zhu Y, Lin Y, Tengwang T, Zhang L. Use of tyrosine kinase inhibitors for paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia: a systematic review and meta-analysis. BMJ Open. 2021;11:e042814. https:\/\/doi.org\/10.1136\/bmjopen-2020-042814.","journal-title":"BMJ Open"},{"key":"461_CR90","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.3324\/haematol.12642","volume":"93","author":"R Santachiara","year":"2008","unstructured":"Santachiara R, Maffei R, Martinelli S, Arcari A, Piacentini F, Trabacchi E, et al. Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor. Haematologica. 2008;93:1252\u20135. https:\/\/doi.org\/10.3324\/haematol.12642.","journal-title":"Haematologica"},{"key":"461_CR91","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1080\/08880018.2020.1759739","volume":"37","author":"S Totadri","year":"2020","unstructured":"Totadri S, Thipparapu S, Aggarwal R, Sharma M, Naseem S, Jain R, et al. Imatinib-induced hypogammaglobulinemia in children and adolescents with chronic myeloid leukemia. Pediatr Hematol Oncol. 2020;37:539\u201344. https:\/\/doi.org\/10.1080\/08880018.2020.1759739.","journal-title":"Pediatr Hematol Oncol"},{"key":"461_CR92","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/ejh.13081","volume":"101","author":"S Ota","year":"2018","unstructured":"Ota S, Matsukawa T, Yamamoto S, Ito S, Shindo M, Sato K, et al. Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic-phase chronic myeloid leukemia. Eur J Haematol. 2018;101:95\u2013105. https:\/\/doi.org\/10.1111\/ejh.13081.","journal-title":"Eur J Haematol"},{"key":"461_CR93","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/S1470-2045(12)70377-7","volume":"13","author":"A Biondi","year":"2012","unstructured":"Biondi A, Schrappe M, De Lorenzo P, Castor A, Lucchini G, Gandemer V, et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol. 2012;13:936\u201345. https:\/\/doi.org\/10.1016\/S1470-2045(12)70377-7.","journal-title":"Lancet Oncol"},{"key":"461_CR94","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1111\/bcp.13933","volume":"85","author":"MM Fachi","year":"2019","unstructured":"Fachi MM, Tonin FS, Leonart LP, Rotta I, Fernandez-Llimos F, Pontarolo R. Haematological adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukaemia: a network meta-analysis. Br J Clin Pharmacol. 2019;85:2280\u201391. https:\/\/doi.org\/10.1111\/bcp.13933.","journal-title":"Br J Clin Pharmacol"},{"key":"461_CR95","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s12185-015-1788-y","volume":"102","author":"T Ando","year":"2015","unstructured":"Ando T, Kojima K, Isoda H, Eguchi Y, Honda T, Ishigami M, et al. Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia. Int J Hematol. 2015;102:379\u201382. https:\/\/doi.org\/10.1007\/s12185-015-1788-y.","journal-title":"Int J Hematol"},{"key":"461_CR96","doi-asserted-by":"publisher","first-page":"334","DOI":"10.5114\/ceji.2020.101265","volume":"45","author":"K Jahnz-R\u00d3\u017byk","year":"2020","unstructured":"Jahnz-R\u00d3\u017byk K, Wi\u0118sik-Szewczyk E, Roli\u0143ski J, Siedlar M, J\u0119drzejczak W, Sydor W, et al. Secondary immunodeficiencies with predominant antibody deficiency: multidisciplinary perspectives of Polish experts. Cent Eur J Immunol. 2020;45:334\u201341. https:\/\/doi.org\/10.5114\/ceji.2020.101265.","journal-title":"Cent Eur J Immunol."},{"key":"461_CR97","doi-asserted-by":"publisher","first-page":"v78","DOI":"10.1093\/annonc\/mdv303","volume":"26","author":"B Eichhorst","year":"2015","unstructured":"Eichhorst B, Robak T, Montserrat E, et al. ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v78-84.","journal-title":"Ann Oncol"},{"key":"461_CR98","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131:2745\u201360.","journal-title":"Blood"},{"key":"461_CR99","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1365-2141.2011.08574.x","volume":"154","author":"JA Snowden","year":"2011","unstructured":"Snowden JA, Ahmedzai SH, Ashcroft J, et al. Guidelines for supportive care in multiple myeloma 2011. Br J Hematol. 2011;154:76\u2013103.","journal-title":"Br J Hematol"},{"key":"461_CR100","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1111\/trf.14656","volume":"58","author":"H Ahn","year":"2018","unstructured":"Ahn H, Shea B, Hutton B, et al. Effectiveness of immunoglobulin prophylaxis in reducing clinical complications of hematopoietic stem cell transplantation: a systematic review and meta-analysis. Transfusion. 2018;58:2437\u201352.","journal-title":"Transfusion"},{"key":"461_CR101","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3389\/fimmu.2016.00317","volume":"7","author":"S S\u00e1nchez-Ram\u00f3n","year":"2016","unstructured":"S\u00e1nchez-Ram\u00f3n S, Dhalla F, Chapel H. Challenges in the role of gammaglobulin replacement therapy and vaccination strategies for hematological malignancy. Front Immunol. 2016;7:317. https:\/\/doi.org\/10.3389\/fimmu.2016.00317.","journal-title":"Front Immunol"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-021-00461-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-021-00461-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-021-00461-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T15:11:25Z","timestamp":1630768285000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-021-00461-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,22]]},"references-count":101,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["461"],"URL":"https:\/\/doi.org\/10.1007\/s40272-021-00461-3","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"type":"print","value":"1174-5878"},{"type":"electronic","value":"1179-2019"}],"subject":[],"published":{"date-parts":[[2021,7,22]]},"assertion":[{"value":"6 July 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"A.H. Groll has received grants from Gilead, Merck, Sharp and Dohme, Pfizer, and Schering-Plough; is a consultant to Astellas, Basilea, Gilead, Merck, Sharp and Dohme, and Schering-Plough; and has served on the speakers\u2019 bureaus of Astellas, Basilea, Gilead, Merck, Sharp and Dohme, Pfizer, Schering-Plough, and Zeneus\/Cephalon. A. Tragiannidis has received grants from Merck, Sharp and Dohme, Gilead, GSK, and Sanofi Pasteur; is a consultant to Pfizer; and has served on the speakers\u2019 bureaus of Gilead, Merck, Sharp and Dohme.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"AT wrote the manuscript, AHG reviewed the whole manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}}]}}